Fixed-Dose Combinations Improve Medication Compliance: A Meta-Analysis



      Compliance with treatment is a sine qua non for successful treatment of chronic conditions like hypertension. Fixed-dose combinations are designed to simplify the medication regimen and potentially improve compliance. However the data on comparison of fixed-dose combination with free-drug regimen to improve patient’s medication compliance is limited.


      We conducted a MEDLINE search of studies using the words fixed-dose combinations, compliance and/or adherence. The inclusion criteria were studies which involved fixed-dose combination versus free-drug components of the regimen given separately. Only studies which reported patient’s compliance were included.


      Of the 68 studies on fixed-dose combinations, only 9 studies fulfilled the inclusion criteria. Two studies were in patients with tuberculosis, 4 in the hypertensive population, 1 in patients with human immunodeficiency virus (HIV) disease and 2 in the diabetic population. A total of 11,925 patients on fixed-dose combination were compared against 8317 patients on free-drug component regimen. Fixed-dose combination resulted in a 26% decrease in the risk of non-compliance compared with free-drug component regimen (pooled relative risk [RR] 0.74; 95% confidence interval [CI], 0.69-0.80; P <.0001). There was no evidence of heterogeneity in this analysis (χ2=14.49, df=8; P=.07). A subgroup analysis of the 4 studies on hypertension showed that fixed-dose combination (pooled RR 0.76; 95% CI, 0.71-0.81; P <.0001) decreased the risk of medication non-compliance by 24% compared with free-drug combination regimen.


      Fixed-dose combination decreases the risk of medication non-compliance and should be considered in patients with chronic conditions like hypertension for improving medication compliance which can translate into better clinical outcomes.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • American Heart Association
        2004 Heart and Stroke Statistical Update. American Heart Association, Dallas, TX2004
        • Neaton J.D.
        • Blackburn H.
        • Jacobs D.
        • et al.
        • Multiple Risk Factor Intervention Trial Research Group
        Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial.
        Arch Intern Med. 1992; 152: 1490-1500
        • Thomas F.
        • Bean K.
        • Guize L.
        • et al.
        Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women.
        Eur Heart J. 2002; 23: 528-535
        • Gaede P.
        • Vedel P.
        • Larsen N.
        • et al.
        Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.
        N Engl J Med. 2003; 348: 383-393
        • Gaede P.H.
        • Jepsen P.V.
        • Larsen J.N.
        • et al.
        The Steno-2 study.
        Ugeskr Laeger. 2003; 165: 2658-2661
        • Dailey G.
        • Kim M.S.
        • Lian J.F.
        Patient compliance and persistence with anti-hyperglycemic therapy: evaluation of a population of type 2 diabetic patients.
        J Int Med Res. 2002; 30: 71-79
        • Veehof L.
        • Stewart R.
        • Haaijer-Ruskamp F.
        • Jong B.M.
        The development of polypharmacy.
        Fam Pract. 2000; 17: 261-267
        • Turner R.C.
        • Cull C.A.
        • Frighi V.
        • Holman R.R.
        • UK Prospective Diabetes Study (UKPDS) Group
        Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49).
        JAMA. 1999; 281: 2005-2012
      1. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
        JAMA. 2002; 288: 2981-2997
        • Materson B.J.
        • Reda D.J.
        • Cushman W.C.
        • et al.
        • The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents
        Single-drug therapy for hypertension in men.
        N Engl J Med. 1993; 328: 914-921
        • Philipp T.
        • Anlauf M.
        • Distler A.
        • et al.
        • HANE Trial Research Group
        Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study.
        BMJ. 1997; 315: 154-159
        • Hansson L.
        • Zanchetti A.
        • Carruthers S.G.
        • et al.
        • HOT Study Group
        Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial.
        Lancet. 1998; 351: 1755-1762
        • Ruzicka M.
        • Leenen F.H.
        Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension.
        Drugs. 2001; 61: 943-954
        • Waeber B.
        Treatment strategy to control blood pressure optimally in hypertensive patients.
        Blood Press. 2001; 10: 62-73
        • Dezii C.M.
        Medication noncompliance: what is the problem?.
        Manag Care. 2000; 9: 7-12
        • Ziegelstein R.C.
        Adherence to medication regimens and recommended lifestyle changes in patients with cardiovascular disease.
        Adv Stud Med. 2003; 3: 150-156
        • Michalsen A.
        • Konig G.
        • Thimme W.
        Preventable causative factors leading to hospital admission with decompensated heart failure.
        Heart. 1998; 80: 437-441
        • Dezii C.M.
        • Kawabata H.
        • Tran M.
        Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes.
        South Med J. 2002; 95: 68-71
        • Breekveldt-Postma N.S.
        • Herings R.M.
        Persistence with antihypertensives related to formulation: the case of nifedipine.
        Ann Pharmacother. 2005; 39: 237-242
        • Blank R.
        • LaSalle J.
        • Reeves R.
        • et al.
        Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study).
        J Clin Hypertens. 2005; 7 (Greenwich): 264-273
        • Blonde L.
        • Wogen J.
        • Kreilick C.
        • Seymour A.A.
        Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin.
        Diabetes Obes Metab. 2003; 5: 424-431
        • Dezii C.M.
        A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension.
        Manag Care. 2000; 9: 2-6
        • Eron J.J.
        • Yetzer E.S.
        • Ruane P.J.
        • et al.
        Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection.
        AIDS. 2000; 14: 671-681
        • Geiter L.J.
        • O’Brien R.J.
        • Combs D.L.
        • Snider Jr, D.E.
        United States Public Health Service Tuberculosis Therapy Trial 21: preliminary results of an evaluation of a combination tablet of isoniazid, rifampin and pyrazinamide.
        Tubercle. 1987; 68: 41-46
        • Melikian C.
        • White T.J.
        • Vanderplas A.
        • et al.
        Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy.
        Clin Ther. 2002; 24: 460-467
        • Su W.J.
        • Perng R.P.
        Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up.
        Int J Tuberc Lung Dis. 2002; 6: 1029-1032
        • Taylor A.A.
        • Shoheiber O.
        Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy.
        Congest Heart Fail. 2003; 9: 324-332
        • Bradburn M.J.
        • Deeks J.J.
        • Altman D.
        Sbe24: metan – an alternative meta-analysis command.
        Stata Tech Bull Reprints. 1998; 8: 86-100
        • Galbraith R.F.
        A note on graphical presentation of estimated odds ratios from several clinical trials.
        Stat Med. 1988; 7: 889-894
        • DerSimonian R.
        • Laird N.
        Meta-analysis in clinical trials.
        Control Clin Trials. 1986; 7: 177-188
        • Burt V.L.
        • Whelton P.
        • Roccella E.J.
        • et al.
        Prevalence of hypertension in the US adult population.
        Hypertension. 1995; 25: 305-313
        • Julius S.
        Worldwide trends and shortcomings in the treatment of hypertension.
        Am J Hypertens. 2000; 13: 57S-61S
        • Chobanian A.V.
        • Bakris G.L.
        • Black H.R.
        • et al.
        The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
        JAMA. 2003; 289: 2560-2572
        • American Diabetes Association
        Standards of medical care for patients with diabetes mellitus.
        Diabetes Care. 2002; 25: 213-229
        • U.K. Prospective Diabetes Study Group
        UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes.
        Diabetes Care. 1998; 21: 87-92
        • Wald N.J.
        • Law M.R.
        A strategy to reduce cardiovascular disease by more than 80%.
        BMJ. 2003; 326: 1419